AUROBINDO PHARMA LTD. - 524804 - Completion Of US FDA Inspection At Unit IV Of APL Healthcare Ltd
The USFDA inspected Unit IV, a formulation manufacturing facility of APL Healthcare Limited, a wholly owned subsidiary of the Company from September 13 to September 19, 2023. At the end of the inspection a Form 483 was issued with one observation which is procedural in nature. AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Copies of Notice published in news papers informing shareholders about transfer of shares to IEPF. AUROBINDO PHARMA LTD. - 524804 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
We bring to your kind notice that the Company has received the letters from the shareholders informing about loss of share certificates. AUROBINDO PHARMA LTD. - 524804 - Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Please refer to the disclosure made by the Company on July 3, 2023 regarding acquisition of certain marketing and manufacturing related authorisations. Further disclosure regarding the aforesaid disclosure are attached as Annexure - I to this disclosure. AUROBINDO PHARMA LTD. - 524804 - Classification Of US FDA Inspection At Our Unit III - Reg.,
The Company''s Unit III received EIR classifying the facility as Voluntary Action Indicated (VAI). AUROBINDO PHARMA LTD. - 524804 - Voting Results Of 36Th Annual General Meeting Of The Company (AGM) Held On August 25, 2023
Please find enclosed voting results of 36 Annual General Meeting of the Company held on August 25, 2023 and scrutinizer''s report. AUROBINDO PHARMA LTD. - 524804 - Shareholder Meeting / Postal Ballot-Outcome of AGM
Proceedings of 36th Annual General Meeting of the Company held on August 25, 2023. 
Accumulate Aurobindo Pharma; target of Rs 907: KR Choksey
KR Choksey recommended accumulate rating on Aurobindo Pharma with a target price of Rs 907 in its research report dated August 24, 2023. AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
This is to inform that the officials of the Company will be participating in the investor / analyst meeting on August 28, 2023.